Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 1-9

  Ruilope, Luis Miguel ^a   Redón, Josep ^b   Schmieder, Roland ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Endothelial dysfunction; ONTARGET; Renin angiotensin system; Telmisartan

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; METOPROLOL; PLACEBO; RAMIPRIL; RENIN; TELMISARTAN;

ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; ERECTILE DYSFUNCTION; GLOMERULUS FILTRATION RATE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; LABORATORY TEST; MICROALBUMINURIA; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; MULTICENTER STUDIES; PROGRAM EVALUATION; RANDOMIZED CONTROLLED TRIALS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 34249889636     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. ACE inhibitors in diabetic nephropathy trialist group. 2001. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med, 134:370-9.
2. American Diabetes Association. 2004. Nephropathy in diabetes. Diabetes Care, 27:79S-83S.
3. Anavekar NS, McMurray JJ, Velazquez EJ, et al. 2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med, 351:1285-95.
4. Anggard E. 1994. Nitric oxide: mediator, murderer, and medicine. Lancet, 343:1199-206.
5. Annuk M, Zilmer M, Fellström B. 2003. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int, 63(Suppl 84):S50-3.
6. Ardaillou R. 1999. Angiotensin II receptors. J Am Soc Nephrol, 10(Suppl 11):S30-9.
7. Amlov J, Evans JC, Meigs JB, et al. 2005. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation, 112:969-75.
8. Asmar R, Gosse P, Topouchian J, et al. 2002. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst, 3:176-80.
9. Barnett AH, Bain SC, Bouter P, et al. 2004. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med, 351:1952-61.
10. Barnett AH. 2005. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol, 42(Suppl 1):S42-9.
11. Battershill AJ, Scott LJ. 2006. Telmisartan: a review of its use in the management of hypertension. Drugs, 66:51-83.
12. Brantsma AH, Bakker SJ, Hillege HL, et al. 2005. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care, 28:2525-30.
13. Brenner BM, Cooper ME, de Zeeuw D, et al. 2001. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345:861-9.
14. Brunner H, Cockcroft JR, Deanfield J, et al. 2005. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:233-46.
15. Burnier M. 2001. Angiotensin II type 1 receptor blockers. Circulation, 103:904-12.
16. Celermajer DS, Sorensen KE, Gooch VM, et al. 1992. Non-invasive detection of endothelial dysfimction in children and adults at risk of atherosclerosis. Lancet, 340:1111-15.
17. Chen R, Iwai M, Wu L, et al. 2003. Important role of nitric oxide in the effect of angiotensin-converting enzyme inhibitor imidapril on vascular injury. Hypertension, 42:542-7.
18. Deanfield J, Donald A, Ferri C, et al. 2005. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens, 23:7-17.
19. de Gasparo M, Catt KJ, Inagami T, et al. 2000. International Union of Phamacology. XXIII. The Angiotensin II receptors. Pharmacol Rev, 52:415-72.
20. de Gasparo M. 2002. Angiotensin II and nitric oxide interaction. Heart Fail Rev, 7:347-58.
21. de Jong PE, de Zeeuw D. 2005. Renoprotective therapy: is it blood pressure or albuminuria that matters? Lancet, 365:913-4.
22. Dzau VJ. 2001. Tissue angiotensin and the pathobiology of vascular disease: a unifying hypothesis. Hypertension, 37:1047-52.
23. Ezzati M, Hoorn SV, Rodgers A, et al. 2003. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet, 362:271-80.
24. Galzerano D, Tammaro P, Cerciello A, et al. 2004. Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens, 18:53-9.
25. Gerstein HC, Mann JF, Yi Q, et al. 2001. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA, 286:421-6.
26. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW, 1994. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res, 74:1141-8.
27. Han Y, Runge MS, Brasier AR, 1999. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res, 84:695-703.
28. Hasdai D, Lerman A. 1999. The assessment of endothelial function in the cardiac catheterization laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz, 24:544-7.
29. Heitzer T, Schlinzig T, Krohn K, et al. 2001. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation, 104:2673-8.
30. Hernandez-Presa M, Bustos C, Ortego M, et al. 1997. Angiotensin-converting enzyme innibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atheroslerosis. Circulation, 95:1532-41.
31. Higashi Y, Sasaki S, Nakagawa K, et al. 2000. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol, 35:284-91.
32. Hillege HL, Fidler V, Diercks GF, et al. 2002. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation, 106:1777-82.
33. Hollenberg NK, Fisher ND, Price DA. 1998. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension, 32:387-92.
34. Ivanova OV, Fomicheva OA, Sergakova LM, et al. 2005. Angiotensin II receptor blocker telmisartan: Effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension. J Int Med Res, 33(Suppl 1):S21A-9.
35. Karalliedde J, Viberti G. 2006. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens, 20:239-53.
36. Klahr S, Morrissey J. 2000. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int, 57:7-14.
37. Klahr S. 2001. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant, 16(Suppl 1):60-2.
38. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens, 16:123-8.
39. Kranzhöfer R, Schmidt J, Pfeiffer CA, et al. 1999. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 19:1623-9.
40. Lee KW, Blann AD, Lip GY. 2006. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute coronary syndromes. Int J Cardiol, 111:302-8.
41. Lewis EJ, Hunsicker LG, Clarke WR, et al. 2001. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345:851-60.
42. McAllister AS, Atkinson AB, Johnston GD, et al. 1999. Basal nitric oxide production is impaired in offspring of patients with essential hypertension. Clin Sci (Lond), 97:141-7.
43. Marui N, Offermann MK, Swenick R, et al. 1993. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest, 92:1866-74.
44. Napoli C, Loscalzo J. 2005. New challenges for ACE-inhibitors in vascular diseases. Drug Design Reviews-Online, 2:485-93.
45. Nishiyarna A, Seth DM, Navar LG. 2002. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol, 13:2207-12.
46. Palmer RM, Ashton DS, Moncada S. 1988. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 333:664-6.
47. Panza JA, Quyyumi AA, Brush JE, Jr., et al. 1990. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med, 323:22-7.
48. Parving HH, Lchnert H, Bröchner-Mortensen J, et al. 2001. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med, 345:870-8.
49. Perico N, Codreanu I, Schieppati A, et al. 2005. The future of renoprotection. Kidney Int Suppl, S95-101.
50. Perticone F, Ceravolo R, Pujia A, et al. 2001. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation, 104:191-6.
51. Raptis AE, Viberti G. 2001. Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes, 109(Suppl 2):S424-37.
52. Redón J, Luque-Otero M, Martell N, et al. 2005. Renin-angiotensin system gene polymorphisms: relationship with blood pressure and microalbuminuria in telmisartan-treated hypertensive patients. Phamacogenomics J, 5:14-20.
53. Roig E, Perez-Villa F, Morales M, et al. 2000. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J, 21:53-57.
54. Ryšavá R, Tesar V, Merta M. 2005. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteinuric patients with chronic kidney disease. Blood Press Monit, 10:207-13.
55. Safar ME, Levy BI, Struijker-Boudier H. 2003. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation, 107:2864-9.
56. Schachinger V, Britten MB, Zeiher AM. 2000. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 101:1899-906.
57. Schmieder RE, 2005. Mechanisms for the clinical benefits of Angiotensin II receptor blockers. Am J Hypertens, 18:720-30.
58. Schmieder RE, Delles C, Mimran A, et al. 2005. Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes. J Hypertens, 23:S147.
59. Sengul AM, Altuntas Y, Kurklu A, et al. 2006. Beneficial effect of lisinopril plus telmisartan patients with type 2 diabetes, microalbuminuria and hypertension. Diabetes Res Clin Pract, 71:210-9.
60. Siragy HM, de Gasparo M, El Kersh M, et al. 2001. Angiotensin-coriverting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension, 38:183-6.
61. Stam F, van Guldener C, Becker A, et al. 2006. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol, 17:537-45.
62. Svolis KA, Lemboussi DSp, Svolis AA, et al. 2002. Telmisartan, an angiotensin II type 1 receptor blocker, improves endothelial function in patients with chronic heart failure [abstract]. J Am Coll Cardiol, 39(9 [Suppl B]), 266B (Abstract 3536).
63. Symeonides P, Koulouris S, Triantafyllou K, et al. 2006. Favourable pleiotropic effects of ramipril and telmisartan on vascular endothelium of diabetics. J Am Coll Cardiol, 45:428A.
64. Taylor AA. 2001. Pathophysiology of hypertension and endothelial dysfunction in patients with diabetes mellitus. Endocrinol Metab Clin North Am, 30:983-97.
65. Teo K, Yusuf S, Anderson C, et al. 2004. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease. (ONTARGET/TRANSCEND) trials. Am Heart J, 148:52-61.
66. Uchida H, Nakamura Y, Kaihara M, et al. 2004. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res, 27:545-50.
67. Viberti G and Wheeldon NM. 2002. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation, 106:672-8.
68. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.
69. Zhou MS, Schulman IH, Raij L. 2004. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol, 24:366-78.